Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, in January 2012 and started operations on July 2, 2012. CPR is Chugai’ s fourth satellite research institute, following others in Japan, South Korea and Singapore.
CPR conducts research on the generation of new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets, and utilizing Chugai’ s proprietary innovative antibody engineering technologies such as the “Recycling Antibody” technology and the “Sweeping Antibody” technology.
|Company Name||Chugai Pharmabody Research Pte. Ltd.
("Pharmabody" is coined from the words pharmaceutical and antibody.)
|Location||3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623|
|Capital||S$ 1.5 million|
|Shareholder||Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.|
|Establishment||January 10, 2012|
|Commencement of Operation||July 2, 2012|
|CEO||Tomoyuki Igawa Ph.D.|
|Number of Employees||113 (as at 1st Jan 2019)|
|Board of Directors||Sir David Lane, Chairman of the Board
Tomoyuki Igawa, Director and CEO
Hisafumi Okabe, Director and COO
Arnold Levine, Director